Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live attenuated measles vaccine + live attenuated Japanese encephalitis vaccine SA 14-14-2
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This refers to the co-administration of two distinct live attenuated vaccines: the SA 14-14-2 Japanese encephalitis vaccine (LJEV) and a standard measles vaccine. The SA 14-14-2 strain is a live, attenuated virus developed by the Chengdu Institute of Biological Products (CDIBP) to prevent Japanese encephalitis, a mosquito-borne flavivirus infection. The measles vaccine used in the referenced study was produced by the Serum Institute of India. PATH (Program for Appropriate Technology in Health) sponsored a Phase 4 clinical trial in Sri Lanka to evaluate the safety and immunogenicity of administering these two vaccines simultaneously to 9-month-old infants. The study aimed to facilitate the integration of the JE vaccine into national immunization programs by demonstrating that co-administration does not interfere with the immune response to either pathogen.
- Other names
- live, attenuated measles vaccine-PATH-Japanese encephalitisLJEV and measles vaccine co-administrationSA 14-14-2 JE vaccine + measles vaccine
Beyond the preview
Go deeper on live attenuated measles vaccine + live attenuated Japanese encephalitis vaccine SA 14-14-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live attenuated measles vaccine + live attenuated Japanese encephalitis vaccine SA 14-14-2.